Author: Dino Mustafić

AbbVie and We Are Pioneer Group Launch Golden Ticket Programme to Help UK Life Science Start-ups Accelerate the Delivery of Life-Changing Innovations to Patients
April 4, 2022 Off

AbbVie and We Are Pioneer Group Launch Golden Ticket Programme to Help UK Life Science Start-ups Accelerate the Delivery of Life-Changing Innovations to Patients

By Dino Mustafić

AbbVie, the global research-driven biopharmaceutical company and We Are Pioneer Group (WAPG), Europe’s largest ecosystem provider for science and innovation businesses, to support the thriving UK life sciences start-up community, has launched a programme designed to help early-stage life science companies commercialise drug discovery and gain access to crucial research space.

FDA approves Cabenuva for some adolescents living with HIV
March 29, 2022 Off

FDA approves Cabenuva for some adolescents living with HIV

By Dino Mustafić

US Food and Drug Administration (FDA) has approved ViiV Healthcare’s Cabenuva (cabotegravir, rilpivirine) for the treatment of HIV-1 in virologically suppressed adolescents (HIV-1 RNA less than 50 copies per milliliter [c/mL]) who are 12 years of age or older and weigh at least 35kg on a stable antiretroviral regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine.

Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
March 29, 2022 Off

Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy

By Dino Mustafić

Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc (US: private) have announced the initiation of a rolling new drug application (NDA) submission to the U.S. Food and Drug Administration (FDA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). Vamorolone for DMD has been granted Fast Track Designation by the FDA.